Skip to main content
Fig. 4 | BMC Medicine

Fig. 4

From: Results of the phase IIa study to evaluate the efficacy and safety of rezivertinib (BPI-7711) for the first-line treatment of locally advanced or metastatic/recurrent NSCLC patients with EGFR mutation from a phase I/IIa study

Fig. 4

A Kaplan–Meier curve for BICR-assessed PFS and investigator-assessed PFS in FAS. B Kaplan–Meier curve for BICR-assessed PFS in patients with and without CNS metastases. C Kaplan–Meier curve for BICR-assessed PFS in patients with EGFR Exon 19 deletion and L858R mutations. Abbreviation: BICR, blinded independent central review; CI, confidence interval; PFS, progression-free survival, FAS, full analysis set; CNS, central nervous system; NC, not calculable

Back to article page

BMC Medicine

ISSN: 1741-7015

Contact us